Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML
Trial details
- Registry ID
- NCT07157514
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AMLNCT07157514 | Actinium Pharmaceuticals | Phase 2, Phase 3 | Not yet recruiting | 2029-02Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |